Erectile Dysfunction Clinical Trial
Official title:
Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED): Comparison of 6 Sessions Once a Week vs 12 Sessions Twice Per Week
The present study aims to identify and compare the efficacy and safety of two different session frequency protocols (once vs twice per week) of low intensity extracorporeal shockwave treatment (LI-ESWT) using Aries ED device, in men with mild-moderate and severe vasculogenic ED, who have previously responded to oral PDE5-Is
This is a randomized, 2 parallel arms, clinical trial. All patients will be PDE5I
users/responders. After 1 month wash-out period, ED patients will be screened, in order to
randomized 42 men with vasculogenic ED who had International Index of Erectile Function ED
(IIEF-ED) domain scores between 6-25 and abnormal penile triplex-based hemodynamic parameters
(peak flow velocity <35cm/sec). Then the 42 pts will be randomized to receive either one or
two shockwave treatment sessions per week, without treatment interval. Every week all
subjects may have at least one attempt for intercourse. All patients will complete 6 weeks of
treatment.
Study visits and duration
Visit 1 (day 0): the basic work-up will take place, including medical and sexual history, as
well as necessary lab tests, if needed. One month wash-out period will follow. During this
period, all subjects will be asked to avoid any drug related to ED (PDE5i) and have at least
2-4 attempts for intercourse. Furthermore, patients will undergo triplex ultrasonography,
unless they have already done so in the last 6 months. all patients will complete the IIEF-ED
domain and will be randomized (1:1) to one of the two parallel study groups, using an online
program. Groups A will receive treatment once per week for 6 weeks (6 sessions totally), and
Groups B will receive treatment two times per week for 6 weeks (12 sessions totally). PDE5i
use is prohibited throughout the study.
Treatment Visits: Patients will receive LI-ESWT , according to the study protocol.Interval
between 2 treatments will be 7+2days for Group A and 3+1 day for Group B.At visit 6 and 12 a
penile ultrasonography will be conducted in order to check for potential adverse events
related to the treatment.
Follow-up visits 1 - 3 (4, 12 and 24 weeks post treatment): Patients will complete the
IIEF-ED questionnaire and return the completed SEP diaries for the last 4 weeks prior to
every visit. Visit data will also be recorded (protocol compliance, adverse events). At Week
12, triplex will be performed by the standard protocol. For Week 4 there is a + 3 days visit
window, whereas for Weeks 12 and 24 there is a + 2 weeks visit window.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |